KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Shares Issued (2016 - 2021)

Historic Shares Issued for Halozyme Therapeutics (HALO) over the last 12 years, with Q4 2021 value amounting to $4.3 million.

  • Halozyme Therapeutics' Shares Issued fell 6619.08% to $4.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $12.5 million, marking a year-over-year decrease of 8022.49%. This contributed to the annual value of $14.0 million for FY2022, which is 1207.72% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Shares Issued of $4.3 million as of Q4 2021, which was down 6619.08% from $4.6 million recorded in Q3 2021.
  • Halozyme Therapeutics' 5-year Shares Issued high stood at $135.3 million for Q2 2017, and its period low was -$602000.0 during Q1 2021.
  • For the 5-year period, Halozyme Therapeutics' Shares Issued averaged around $11.9 million, with its median value being $4.2 million (2021).
  • In the last 5 years, Halozyme Therapeutics' Shares Issued plummeted by 23789.47% in 2017 and then soared by 20640000.0% in 2018.
  • Over the past 5 years, Halozyme Therapeutics' Shares Issued (Quarter) stood at -$1000.0 in 2017, then surged by 206400.0% to $2.1 million in 2018, then surged by 294.13% to $8.1 million in 2019, then skyrocketed by 56.78% to $12.7 million in 2020, then crashed by 66.19% to $4.3 million in 2021.
  • Its last three reported values are $4.3 million in Q4 2021, $4.6 million for Q3 2021, and $4.2 million during Q2 2021.